Founded at the Abramson Cancer Center at the University of Pennsylvania

Approaches to Foster Economic Sustainability of Precision Cancer Medicine and Cell Therapies

This initiative examines the high price effectiveness and value of precision cancer medicine and cell and gene therapies. Projects have included a major symposium on cell and gene therapy, and deep dives into specific issues including policy proposals  to address the high costs of cancer drugs and policy proposals to optimize payment for novel, impactful therapies, like CAR-T.

The work to date has been widely disseminated to inform national policy discussions of the high price of cancer therapies, cell therapy and gene therapy.

Steven Joffe, MD, MPH; Abby Alpert, PhD; Dan Polsky, PhD; Christopher Manz, MD; David Porter, MD; and Justin Bekelman, MD.

Abramson Cancer Center Cancer Control Program, Radiation Oncology, Hematology and Oncology, Medical Ethics and Health Policy, The Wharton School, Leonard Davis Institute of Health Economics, and the Center for Cell Therapy and Transplantation.

Philanthropically funded Penn Gant Consortium Initiative and the New York Community Trust

New Penn Precision Cancer Medicine Group Convenes in Philadelphia
Two Dozen Top Experts Focus on the Economics of a Burgeoning Field

Managing The Coming Tsunami of Genomic and Cellular Therapy Cost and Access Issues
Penn LDI ‘Cost of a Cure’ Conference Convenes Top Experts Including FDA Commissioner

Penn Medicine Magazine Special Edition on LDI and Cancer Research
Cancer and the Costs of Special Treatment

Payment Models and Affordability

Related Publications

Transforming Cancer Care

Learn More right facing arrow